BLISS GVS PHARMA LTD. - 506197 - Appointment Of Secretarial Auditor.
Re-appointment of M/s. AVS & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company for the financial year 2021-2022.31-07-2021
31-07-2021
BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Change in Directorate
1) Re-appointment of Mrs. Shruti Vishal Rao (DIN: 00731501) as Whole-Time Director of the Company for another period of three years with effect from April 01, 2022 to March 31, 2025. 2) Re-appointment of Dr. Vibha Gagan Sharma (DIN: 02307289) as Whole-Time Director of the Company for another period of three year with effect from January 27, 2022 to January 26, 2025.31-07-2021
Bliss GVS Pharma Ltd - 506197 - Unaudited Standalone And Consolidated Financial Result For The Quarter Ended June 30, 2021
We would like to inform you that, Board Meeting of the Company was held today i.e. Saturday, July 31, 2021 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the matters as per attachment.31-07-2021
Bliss GVS Pharma Ltd - 506197 - Board Meeting Intimation for Board Meeting Intimation For Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2021
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Saturday, July 31, 2021 at the registered office of the Company to consider and approve, inter alia, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2021. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01, 2021 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30, 2021.23-07-2021
BLISS GVS PHARMA LTD. - 506197 - Shareholding for the Period Ended June 30, 2021
Bliss GVS Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here20-07-2021
Bliss GVS Pharma Ltd - 506197 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0101 Name of the Signatory :- Aditi BhattDesignation :- Company Secretary and Compliance Officer20-07-2021
Bliss GVS Pharma Ltd - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2021.14-07-2021
Bliss GVS Pharma Ltd - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose copies of newspaper advertisement of notice published in The Free Press Journal (English) and Navshakti (Regional) on July 09, 2021, concerning the proposed transfer of unclaimed final dividend 2013-2014 and its corresponding shares to IEPF Authority, pursuant to Section 124(6) of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time.09-07-2021
Bliss GVS Pharma Ltd - 506197 - Notice To Shareholders W.R.T. Transfer Of Unclaimed Final Dividend 2013-2014 And Its Corresponding Shares To Investor Education And Protection Fund (IEPF) Authority
In accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose copy of the communication sent to those concerned shareholders, whose dividend have remain unclaimed for a period of seven consecutive years or more, concerning the proposed transfer of unclaimed final dividend 2013-2014 and its corresponding shares to the IEPF Authority in pursuance of section 124(6) of the Companies Act, 2013 read with Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.09-07-2021
BLISS GVS PHARMA LTD. - 506197 - Notice To Shareholders W.R.T. Transfer Of Unclaimed Final Dividend 2013-2014 And Its Corresponding Shares To Investor Education And Protection Fund (IEPF) Authority
In accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose copy of the communication sent to those concerned shareholders, whose dividend have remain unclaimed for a period of seven consecutive years or more, concerning the proposed transfer of unclaimed final dividend 2013-2014 and its corresponding shares to the IEPF Authority in pursuance of section 124(6) of the Companies Act, 2013 read with Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.09-07-2021